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Background: Hepatocellular carcinoma (HCC) has been associated with diabetes and obesity, but a possible
connection with the metabolic syndrome (MetS) and its potential interaction with hepatitis and cirrhosis are open
to discussion. Our previous investigations have shown that GGPPS1 plays a critical role during hyperinsulinism. In
this report, the expression and distribution of GGPPS1 in liver cancer, and its clinical significance were investigated.
Methods: 70 patients with hepatocellular carcinoma (HCC) were included in this study. Three different types of
tissues from each HCC patient were assembled immediately after surgical resection: tumor-free tissue >5 cm far
from tumor edge (TF), adjacent nonmalignant tissue within 2 cm (AT), and tissue from the tumor (TT). Normal liver
tissues from 10 liver transplant donors served as healthy control (HC) while 10 patients with liver cirrhosis as
cirrhosis control (CC). The expression and distribution of GGPPS1 were detected by immunohistochemistry, western
blots, or real-time PCR. The relationship between the expression of GGPPS1 and clinic pathologic index were
analyzed.
Results: We found that GGPPS1 was intensified mainly in the cytoplasm of liver tumor cells. Both the expression of
GGPPS1 mRNA and protein were upregulated in TT comparing to AT or TF. Meanwhile, HCC patients with cirrhosis
had relative higher expression of GGPPS1. In addition, many pathologic characters show close correlation with
GGPPS1, such as tumor stage, vessel invasion, and early recurrence.
Conclusion: GGPPS1 may play a critical role during the development of HCC from cirrhosis and is of clinical
significance for predicting biological character of HCC.
Background
Liver cancer in men is the fifth most frequently diagnosed
cancer and ranks the second cause of cancer-related death
worldwide [1]. Liver cancer comprises diverse, histological
distinct primary hepatic neoplasms while hepatocellular
carcinoma (HCC) represents the major histological type
and likely accounts for 75% cases [2]. The etiology of
HCC is likely to involve interactions between multiple risk
factors, including hepatitis B or C virus (HBV or HCV),
hepatosteatosis, and long-term exposure to toxic che-
micals, leading to liver injury and inflammation [3-5].
Persistent inflammation fosters a chronic liver disease
condition that eventually culminates in liver cirrhosis. In
fact, cirrhosis is present in about 80–90% of HCC patients
and is thereby the largest risk factor [6]. With the recent
worldwide epidemic of obesity and metabolic syndrome
[7,8], it has been reported that underlying insulin re-
sistance and fatty liver disease may potentially increase the
risk and worsen HCC outcomes [9].
The lethality of liver cancer partially results from its
resistance to existing anticancer agents and lack of bio-
markers that can detect surgically resectable incipient
nodule. Recently, improved knowledge of signaling
pathways that regulate tumor cell proliferation,
* Correspondence: xuebin@nju.edu.cn; drdingyitao@sina.com
†Equal contributors
3Jiangsu Key Laboratory of Molecular Medicine of the School of Medicine,
Nanjing University, National Resource Center for Mutant Mice and MOE Key
Laboratory of Model Animals for Disease Study, Model Animal Research
Center, Nanjing, Jiangsu Province 210093, P.R. China
1Department of Hepatobiliary Surgery, the Affiliated Drum Tower Hospital, Medical
School of Nanjing University, Nanjing, Jiangsu Province 210008, P.R. China
Full list of author information is available at the end of the article
© 2014 Yu et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited.
Yu et al. BMC Cancer 2014, 14:248
http://www.biomedcentral.com/1471-2407/14/248differentiation, angiogenesis, and metastasis has led to
several possible therapeutic targets. Hence, interference of
MAPK, PI3K/AKT/mTOR, WNT/b-catenin and IGF
pathways are suggested to be promising therapies [10].
Additionally, Statin can decrease synthesis of downstream
products in mevalonate pathway, thus benefits in the che-
moprevention and management of HCC. As intermediate
isoprenoid, GGPP can overcome the inhibition of COX-2
protein expression by simvastatin [11]. Additionally, it has
been reported that inhibition of GGPPS induced autoph-
agy in prostate cancer [12] and decreased breast cancer
cell migration [13]. However, no study on the relationship
between expression level of GGPPS and HCC biological
character has been reported till date. Therefore, we
hypothesized that GGPPS1 could be correlated with car-
cinogenesis of HCC.
Mevalonate pathway can produce isoprenoids that are
vital for diverse cellular functions, ranging from choles-
terol synthesis to growth control [14]. GGPPS1 is a branch
point enzyme in this pathway and catalyzes the synthesis
of all-trans-geranylgeranyl diphosphate (GGPP), the 20
carbon isoprene moieties post-translationally incorporated
into several proteins, including many members of the Ras
and Rho family [15]. According to our previous study, in
the pathogenesis of cigarette smoke-related pulmonary
disease and type 2 diabetes mellitus (T2DM), GGPPS1
can enhance Ras prenylation and membrane association,
further leading to pulmonary inflammation and insulin
resistance through MAPK pathway [16,17]. However,
the contribution of GGPPS1 to HCC remains largely
unexplored. Considering the critical role of these small
GTPases in tumor genesis and metastasis [18-20], we
propose that GGPPS1 may have involvement in the de-
velopment of HCC and can be used as biomarker in
diagnose.
In this study, we investigated the expression and dis-
tribution of GGPPS1 in liver tissues and tumor tissues
from HCC patients. Additionally, the correlation of
protein level with clinicpathologic factors was analyzed to
determine whether it is an independent prognostic marker
for predicting clinical outcomes of HCC in patients.
Methods
Patients and samples
Between January 2005 and August 2012, 70 patients with
hepatocellular carcinoma (HCC) were included in this
study in the Department of Hepatobiliary Surgery of
Drum Tower Hospital. None of the patients had under-
gone any preoperative therapies. Three different types of
tissues from each HCC patient were assembled immedi-
ately after surgical resection: tumor-free tissue >5 cm far
from the tumor edge (TF), adjacent nonmalignant tissue
within 2 cm (AT), and tissue from the tumor (TT).
Areas of tissue necrosis and hemorrhage were excluded.
Normal liver tissues from 10 liver transplant donors
served as healthy control (HC) while 10 patients with
liver cirrhosis as cirrhosis control (CC).
All of the tissue samples were snap frozen immediately
after resection and kept in liquid nitrogen until they
were used for experiments. A senior pathologist did his-
topathologic examination of all specimens with expe-
rience in HCC pathology (Dr. WU Hongyan), who was
unaware of the preoperative clinical data and immu-
nostaining results. Tumor differentiation was assessed
according to Edmonson and Steiner grading system.
Serial sections of the tumors and surrounding liver were
examined to identify any tumor encapsulation, micro-
scopic venous invasion, and microsatellite lesions. The
degree of HCC invasiveness was verified according to
the invasiveness scoring system for HCC. Tumor stage
was defined according to tumor-node-metastasis (TNM)
classification of the American Joint Committee on Inter-
national Union against Cancer.
Preoperative clinical and laboratory, and pathological
data were prospectively assembled for each patient in
our HCC database. All patients were followed and
monitored regularly for tumor recurrence by alpha-
fetoprotein level (monthly) and chest X-ray, together
with B ultrasonic or computed tomography scan (every
3 months). A diagnosis of recurrence was based on typi-
cal imaging appearance in computed tomography scan
and an elevated alpha-fetoprotein level. All of the pa-
tients were followed until death or until the study clo-
sing date of January 1st, 2013.
This study was approved by the Scientific Research
Ethics Committee of the affilisted Drum Tower Hospital,
Medical School of Nanjing University, and an informed
consent was obtained from all participants.
Immunohistochemistry
Formalin-fixed and paraffin-embedded HCC sections with
at h i c k n e s so f4μm were dewaxed in xylene and graded
alcohols, hydrated and washed in phosphate buffered
saline (PBS). After pretreatment in a microwave oven, en-
dogenous peroxidase was inhibited by 3% hydrogen per-
oxide in methanol for 20 min, followed by avidin-biotin
blocking using a biotin-blocking kit (DAKO, Germany).
Slides were then immunoassayed with the antibodies to
human GGPPS1 (1:200; Proteintech), CD34 (1:300; Santa
Cruz Biotechnology), VEGF165 (1:100, Santa Cruz), p53,
PCNA, EGFR, or COX-2 (1:200; DAKO). A subsequent
reaction was performed with biotin-free HRP enzyme-
labeled polymer from an En Vision plus detection system
(DAKO, CA). Positive reactions were visualized with
diaminobenzidine (DAB) solution followed by counter-
staining with hematoxylin. Negative controls were per-
formed using non-immune goat serum instead of the
primary antibodies.
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the GGPPS1, PCNA, EGFR, or COX-2 protein levels. A
brown particle in nuclei was considered as positive labe-
ling. Immunostain was scored using a 4-point scale (0–4)
system according to the intensity of staining and the per-
centage of positive cells. IHC evaluation was performed
according to the method described before [21]. For each
case, 1000 cells were randomly selected and scored. HCC
sections were observed under light microscopy and the
staining intensity scores were independently assessed by 2
pathologists (Dr. CHEN Jun and WU Hongyan).
Real-time PCR
Acid guanidine thiocyanatephenol-chloroform extraction
was used to isolate total RNA from liver tissues [22].
With random hexamer primers, the maximum allowed
volumes of RNA samples were transcribed with ExScript
RT reagent kit (TaKaRa) according to the manufacturer’s
protocol. RNA samples without reverse transcription
were used as negative controls.
PCR Primers and probes for human GGPPS1 and 18S
genes were designed with Primer Express 2.0 software
(Applied Biosystems) and synthesized by Genecore. The
basic information on primers, including gene name,
forward primer, reverse primer are the following: GGPPS1,
CCAGGTAAACAAGTGAGAACCAA, CGTCGGAGTT
TTGAGTTGTCT, and 18S, GTCTGTGATGCCCTTA
GATG, AGCTTATGACCCGCACTTAC. For the am-
plification of GGPPS1 and 18S genes, real-time PCR was
done in triplicate for each sample in a 20 μlr e a c t i o nm i x -
ture, which consisted of template DNA (2 μl), primers
(900 nmol/L), probe (250 nmol/L), Mg
2+ (5 mmol/L) and
Ex Taq HS (0.1 units/AL; ExScript Real-time PCR Kit,
TaKaRa). PCR was done in a Stratagene Mx3005P instru-
ment using the following thermal cycles: one cycle of
1 min at 95°C, 40 cycles of 15 s at 95°C, 15 s at 58°C and
30s at 72°C. Amplification efficiency of each individual
sample was calculated by version 7.0 of LinRegPCR
program (a gift from C.R.Ramakers, 3 Academic Me-
dical Centre, University of Amsterdam, Amsterdam, the
Netherlands). According to the method tested by Pfaffl,
the relative expression ratio of a targeted gene was cal-
culated based on efficiency and the Ct compared with a
reference gene (18S).
Western blots
Tissue lysates were boiled with 6×sodium dodecyl sulfate
(SDS) loading buffer and then fractionated by SDS-PAGE.
The proteins were transferred to PVDF membrane and in-
cubated with 5% of non-fat milk. The membranes were
then incubated overnight at 4°C with primary antibody
against human GGPPS1 (Proteintech, at a 1:200 dilution)
or beta-actin (Boster, at a 1:1000 dilution). After being
washed with PBST for 30 min, the membrane was probed
with HRP-conjugated secondary antibody (Boster, at a
1:10000 dilution) for 1 h at room temperature. ECL detec-
tion reagent was used to demonstrate the results.
Statistical analysis
Data were expressed as mean±SD with the range given in
parentheses, or categorized. Statistical comparisons were
done using the Mann–Whitney U test, t test, ANOVA, or
linear regression when data were normally distributed.
Wilcoxon matched paired test was used to determine the
significance of GGPPS1 expression among different kinds
of liver tissues. χ2 test was performed to analyze the
correlation between GGPPS1 expression and clinic patho-
logical parameters. All statistical procedures were done
using SAS (version 9.0; SAS, Inc.). Values of p<0. 05we re
considered statistically significant.
Results
Characteristics of patients with HCC
In 70 patients (62 males and 8 females; median age,
54.09 years) who underwent curative resection (60 cases
for regular hepatectomy and 10 for orthotopic liver trans-
plantation), the average tumor size was 7.59×5.88 cm.
Liver cirrhosis was detected in 42 patients, 9 patients had
chronic hepatitis, and the remaining 19 patients without
hepatitis or cirrhosis.
The etiologies of underlying liver diseases were hepatitis
B in 42 patients, hepatitis C in 6 patients, and mixed viral
infection in 3 patients. According to International Union
Against Cancer recommendation, 15 patients were classi-
fied as stage I, 19 patients as stage II, 24 patients as stage
III, and 12 patient as stage IV. Sixty-one patients were in
child’s class A, 6 in class B and 3 in class C. The basic in-
formation of all the patients was attached in Additional
file 1.
Higher expression of GGPPS1 in tumor tissue comparing
to adjacent nonmalignant tissues
To investigate the expression of GGPPS1 in HCC patients,
Q-PCR was used to analyze the expression of GGPPS1
mRNA in 34 paired TT, AT and TF liver tissues. The re-
sults demonstrated that GGPPS1 mRNA was upregulated
in 85.29% TT compared with TF and AT, and the mean
relative level of GGPPS1 mRNA in TT and ATcomparing
to TF was 5.69 and 1.28 (Figure 1A). Consistently, western
blots showed that protein level of GGPPS1 in TT was no-
ticeably higher than that in TF and AT in 11 of the 15 pa-
tients (Figure 1B). However, there was no difference of
GGPPS1 in mRNA and protein level between AT and TF
(Figure 1C). To further confirm the results, immuno-
histochemistry was performed to assess the expression of
GGPPS1. GGPPS1 was positively stained in 67.14% of TT,
which was higher than that in AT (30%), TF (24.29%), CC
(30%), and HC (zero) (Figure 1D, p<0. 00 1) .
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tumor cells
Our previous investigations reported that GGPPS1 was
also found in airway epithelium, alveolar epithelial cells,
and invasive inflammatory cells in cigarette smoke-
related lungs [16]. The distribution and expression of
GGPPS1 in paired TT, ATand TF (n= 70), cirrhotic liver
as cirrhosis control (CC, n =10), and normal liver as
healthy control (HC, n =10), was evaluated with immu-
nohistochemistry. The positive staining of GGPPS1
mainly existed in cytoplasm of tumor cells (Figure 2A
and B). Of note, GGPPS1 signals were less in the hepa-
tocytes in AT and TF (Figure 2C and D, E and F). In cir-
rhotic liver or normal, GGPPS1 was negative or weakly
positive (Figure 2G and H, I and J). Therefore, GGPPS1
mainly distributes in the cytoplasm of liver tumor cells.
Expression of GGPPS1 in TT is associated with cirrhosis
and GGPPS1 in AT
We checked the GGPPS1 distribution in TT and AT
among the patients with or without cirrhosis or hepa-
titis. The proportion of GGPPS1-positive distribution in
TT is higher in the patients with cirrhosis than in the
patients without cirrhosis (p =0.0484), while no statistic
difference was found about GGPPS1 in TT between the
patients with and without hepatitis (p=0.4428) (Table 1).
Positive correlation between the expression of GGPPS1
in TT and AT was also found. However, No statistic dif-
ference was found about GGPPS in AT between the pa-
tients with and without cirrhosis/hepatitis (p =0.8314/
0.1307).
Expression of GGPPS1 is associated with biological
character of HCC
To determine the clinical significance of GGPPS1 expres-
sion in HCC, the relationship between GGPPS1 expression
and clinic pathological features was analyzed. Significant
correlations were found between GGPPS1 expression
and variables including TNM stage (p=0.0059), T stage
(p=0.0041), vessel invaded (p=0.0009), early recurrence
(p=0.0065), and recurrence (p=0.0444) (Table 2). In a
word, HCC patients with higher GGPPS1 expression had a
higher tendency to be with advanced stage, vessel invaded,
early recurrence, or recurrence. There were no statistical
connections between GGPPS1 expression in TTand other
clinic pathological parameters, such as age, gender, AFP,
tumor differentiation, tumor necrosis, nodal number,
CD34, p53, PCNA, VEGF, EGFR, or COX-2 (p>0 .0 5 ,
Additional file 2). Moreover, there were no statistical
correlations between GGPPS1 expression in AT and
clinic pathological parameters, except gender (p>0 .0 5 ,
Additional file 2).
Figure 1 Expression of GGPPS1 in liver tissues and tumor tissues of the patients with hepatocellular carcinoma. (A) Relative expression
level of GGPPS1 mRNA in 34 paired adjacent nonmalignant (AT) and tumor tissues (TT) comparing with tumor-free (TF) by qRT-PCR. Logarithm of
fold change is shown. (B) Representative western blots analysis of GGPPS1 expression in 15 paired TF, AT and TT. (C) Semiquantitative western
blots analysis of lysates of 15 paired tissue samples is shown. The mean protein expression level was significantly increased in TT compared with
TF. (D) Immunohistochemical staining of anti-GGPPS1 antibody in paired AT and TT (n=70), cirrhotic liver as cirrhosis control (CC, n= 10), and
normal liver as healthy control (HC, n=10) is shown.
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Our study showed that GGPPS1 mRNA and protein
expression levels were remarkably upregulated in HCC
tissues, while it was much lower in paired adjacent
nonmalignant and tumor free tissues and absent in
healthy samples. Study of HCC epidemiology shows that
more than 80% hepatitis B and C patients presenting
with HCC are already cirrhotic [23]. In this study,
Figure 2 Distribution of GGPPS1 antigen in liver tissues and tumor tissues of the patients with hepatocellular carcinoma. The
representative images are shown from tumor tissues (TT, A and B), adjacent non-tumor tissues (AT, C and D), tumor free tissues (TF, E and F), cirrhotic
controls (CC, G and H), healthy controls (HC, I and J) tissues. Magnification: A, C, E, G, I 100×, B, D, F, H,a n dJ 200×.
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GGPPS1 and hepatitis, GGPPS1 was confirmed to be
related with cirrhosis, pointing to the possibility that
GGPPS1 might contribute to HCC through cirrhosis.
The characterization of genes that are differentially
expressed between tumor and adjacent nonmalignant
tissues is now considered meaningful in diagnosing the
processes from normal to neoplastic. Immunohistoche-
mistry results demonstrated that patients with higher
GGPPS1 expression in TT had later pathology stage,
which suggested that the upregulation of GGPPS1 could
reflect lower differentiation and more aggressive clinical
behavior in HCC. Therefore, GGPPS1 could act as a
novel and useful biomarker reflecting incipient nodule
and prevent deterioration from cirrhosis to HCC by sur-
gical resection in early stage.
GGPPS is responsible for producing GGPP, and pre-
vious studies demonstrated that GGPPS1 was essential
for prenylation modification of Ras [17]. Ras proteins
are being studied intensively in many laboratories be-
cause Ras-Raf-MAPK cascades are key intracellular sig-
naling pathways involved in the regulation of normal cell
functions and also vital in pathological stress-exposure
processes. Thus, any aberrant regulation of MAPK cas-
cades may render cells insensitive to regulatory signals
and contribute to tumor genesis [24]. In our study, both
the expression of GGPPS1 mRNA and protein were dra-
matically upregulated in tumor tissues, and patients with
higher expression of GGPPS1 showed advanced tumor
stage and vessel invasion. We therefore hypothesized
that aberrant prenylation of Ras could enhance liver car-
cinogenesis through overactivation of MAPK pathway.
Table 1 The correlation among cirrhosis, hepatitis and GGPPS1 antigen in tumor tissues and adjacent non-tumor
tissues of the patients with HCC
Variable Category GGPPST p GGPPSA p
Negative Positive Negative Positive
Cirrhosis No 13 15 20 8
Yes 10 32 0.0484 29 13 0.8314
Hepatitis No 10 16 21 5
Yes 13 31 0.4428 28 16 0.1307
GGPPSA Negative 17 32
Positive 6 15 <. 0001
GGPPST represents GGPPS1 antigen in tumor tissues, and GGPPSA represents GGPPS1 antigen in adjacent non-tumor tissues.
Table 2 Clinic pathological factors and expression of GGPPS1 antigen in tumor tissues and adjacent non-tumor tissues
of the patients with HCC
Variables Category GGPPST p GGPPSA p
Negative Positive Negative Positive
AFP <40 12 23 23 12
>=40 11 24 0.7991 26 9 0.4339
Stage 1 10 5 11 4
2 71 2 1 54
3 51 9 1 68
4 1 11 0.0059 7 5 0.6161
Tumor 1 10 5 11 4
2 71 1 1 35
3 51 9 1 77
4 1 12 0.0041 8 5 0.8951
Vessel invaded No 18 17 27 8
Yes 5 30 0.0009 22 13 0.1922
Early recurrence No 14 43 42 15
Yes 9 4 0.0065 7 6 0.1421
Recurrence No 11 34 34 11
Yes 12 13 0.0444 15 10 0.1736
GGPPST represents GGPPS1 antigen in tumor tissues, and GGPPSA represents GGPPS1 antigen in adjacent non-tumor tissues.
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RhoA has also been reported to be involved in the
progression and metastasis in HCC [25]. Clinic results
strongly suggested that increased RhoA expression in
HCC was correlated with vessel invasion and cell dif-
ferentiation of HCC [26]. In our study, there was a sharp
increase of GGPPS1 in patients with vessel invasion and
later tumor stage, suggesting that upregulated GGPPS1
could elevate prenylated RhoA, further accelerating
invasion and intrahepatic metastasis. Moreover, studies
demonstrated that RhoA GTPase might regulate cell sur-
vival via Bcl2 family proteins in a p53-independent man-
ner [27], indicating that higher expression of GGPPS1
could inhibit apoptosis and induce proliferation, therefore
resulting in tumor genesis though a RhoA-mediated
mechanism.
Recently, it has been demonstrated that LTsc1KO mice
with hyperactive mTORC1 signaling display metabolic
abnormalities and subsequently develop HCC [28,29].
Considering that activated Cdc42 and Rac1 potently
stimulated S6K1 in vitro and in vivo [30], we hypo-
thesize that aberrant protein prenylation caused by
GGPPS1 may accelerate liver carcinogenesis by regu-
lating Cdc42/Rac1 activation of mTORC1 and subse-
quent aberrant lipid homeostasis. However, our results
showed no relation between GGPPS1 and CD34, p53,
PCNA, VEGF, EGFR or COX-2, which were widely used
in clinical pathology. The molecular basis for this obser-
vation remains to be elucidated.
Conclusion
In summary, the present study revealed the role of
GGPPS1 in HCC, further supporting the impact of preny-
lation during neoplastic development and progression.
Notably, GGPPS1 showed significant correlation with
pathology stage, cirrhosis, vessel invasion, and recurrence.
This establishes feasibility of GGPPS1 in predicting bio-
logical character of HCC in patients with cirrhosis. Our
results also indicated that disturbance of prenylation of
Ras and Ras-related small GTP-binding proteins may
serve as a therapeutic strategy. Once upstream and down-
stream signaling pathways are understood, these findings
will be practical for prognosis and prevention of deterio-
ration of incipient lesion.
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